Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy

Abstract Introduction Immune checkpoint inhibitor (ICI)‐based treatment regimens have become the standard of care for first‐line treatment of metastatic epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild‐type non‐small cell lung cancer (NSCLC). Nevertheless, most patients...

Full description

Bibliographic Details
Main Authors: Jia Liu, Minjiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Thoracic Cancer
Subjects:
immune checkpoint inhibitors
non‐small cell lung cancer
pembrolizumab
plinabulin
second‐line treatment
Online Access:https://doi.org/10.1111/1759-7714.14806

Internet

https://doi.org/10.1111/1759-7714.14806

Similar Items